Market capitalization | $21.70b |
Enterprise Value | $21.26b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.88 |
P/S ratio (TTM) P/S ratio | 14.17 |
P/B ratio (TTM) P/B ratio | 23.23 |
Revenue growth (TTM) Revenue growth | 54.94% |
Revenue (TTM) Revenue | $1.53b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
20 Analysts have issued a Natera, Inc. forecast:
20 Analysts have issued a Natera, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,532 1,532 |
55%
55%
|
|
Gross Profit | 883 883 |
109%
109%
|
|
EBITDA | -205 -205 |
56%
56%
|
EBIT (Operating Income) EBIT | -242 -242 |
52%
52%
|
Net Profit | -215 -215 |
57%
57%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Stephen Chapman |
Employees | 3,293 |
Founded | 2004 |
Website | www.natera.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.